Recs

3

Are the Shorts Wrong About Dendreon?

By | More Articles
December 11, 2012 | Comments (3)

Dendreon (NASDAQ: DNDN  ) is a constant target for short-sellers, with shares down by a third for 2012 and the two-year graph looking even worse. But with a very important clinical trial on the way for Dendreon's Provenge in sequence with Johnson & Johnson's (NYSE: JNJ  ) drug Zytiga in a pre-chemo cancer indication, is the short-selling over? Motley Fool health care analyst David Williamson tells us why the shorts might be wrong on this one and why Dendreon might be due for a turnaround.

Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? David Williamson answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid. Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (3) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 13, 2012, at 1:55 PM, never2dull4u wrote:

    Shorts don't care if they are right or wrong. They just want to bash the stock and profit from it.

    Isnt' that what SA and Motley Fools do best...?

  • Report this Comment On December 13, 2012, at 2:56 PM, lebronz wrote:

    Ahh Brenton, the wealthy hedgefund(s) shorting dndn over the last 12-14 months are not/have not COVERED so they are not/have not PROFITED. The short interest still stands at 44million

    http://www.nasdaq.com/symbol/dndn/short-interest

    This hedgefund stock price management plan began in Oct 2011 when short interest stood at 23million (not shown on Nasdaq anymore).

    Short interest then climbed over the next 12-14 months and peaked at 47million on Nov 2012. That's 24 million shorted since last Oct 2011!

    Flooding the market or selling millions of dndn shares steadily over each month drives the stockprice downward. Its simple math and not a conspiracy theory like many think. It simply illustrates desperate greed for the meager 154million shares outstanding and because dndn refuses wallstreets request to do another secondary offering.

    Only powerful, rich hedgies can spend $300-$400 million and pull off this shorting millions plan...A plan that gives the illusion of trouble within a promising company [eg; plant closings, layoffs, competitive threats (altho docs will sequence therapies to prolong the dying mans life to da MAX!) declining sales even tho YoY sales are spectacular at $48M (2010) $216M (2011) and 2012 on pace to do $322M)].

    You both are beginning to see & believe. Morpheous would b proud.

    CEO JJ understands how to underpromise & overdeliver and this year was devoted to underpromising. When you have 12 years market exclusivity under Obamacare (no threat from biosimilar) and you're only 2.6 years from when Provenge was approved and mfg is still ramping along with the 5000-12000 urologists becoming aware.... hedgies have to do something to get there shares b4 word gets out.

    When you have a company treating just a fraction of the 30k men newly diagnosed with mCRPC (Excluding the 60k living w/ mCRPC as these men typically live 2 years), that gets hedgies eyes rolling $$$.

    Keep the dndn videos coming on dndn every other day. I like seeing what color sweater David wears next.

    Leb

    Ps: Remember, when you have loaded wall street and all their ponzi schemes, high freq trading, insider trading, Libor manipulation, Credit rating agency scams, and the occasional flash crash....talking negative about the next big biotech and shorting the hell out of her over 4 quarters is a walk in the park 4them...

    :-D

  • Report this Comment On December 13, 2012, at 3:13 PM, lebronz wrote:

    Oh, and David...

    Do we have to buy your "premium" report on dndn?

    Can't you simply tell everyone in your kewull free video articles to BUY DNDN NOW!?

    Tell your audience things like even with NJ plant closing, dndn has a 160k and a 180k sq ft., brand new, high tech mfg plants in GA and CA that can produce up to $1B in Provenge..Info like that shud b free, don't u agree?

    gltu sir

    Leb

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 2148834, ~/Articles/ArticleHandler.aspx, 5/21/2013 12:55:34 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
DOW 15,335.28 -19.12 -0.12%
S&P 500 1,666.29 -1.18 -0.07%
NASD 3,496.43 -2.54 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/20/2013 4:00 PM
DNDN $3.94 Down -0.07 -1.75%
Dendreon Corp CAPS Rating: **
MDVN $47.41 Down -0.12 -0.25%
Medivation, Inc. CAPS Rating: **
JNJ $88.01 Down -0.08 -0.09%
Johnson & Johnson CAPS Rating: *****

Advertisement